[Natrium valproate, antiepileptic effect--serum concentration. A controlled study].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to A Würtz-Jørgensen.
Explore the source record for details and available documents.
Clinical effects at three different serum levels of sodium valproate (VPA) were compared in a triple-blind, multiple crossover trial comprising 13 epileptic inpatients. Patients were selected regardless of seizure type, and all were in concomitant antiepileptic treatment, which was kept constant throughout the study. A significant relationship between the decrease in number of seizures and increasing VPA serum level was demonstrated. The relationship between VPA dose and serum level was curvilinear. Statistical evaluation of patients by seizure type in relation to clinical effect of VPA was only possible for secondary generalized seizures. Between phenytoin, phenobarbital, and carbamazepine and the different VPA serum levels no interactions could be demonstrated. Recorded side effects were always mild and transient. No obvious correlation between side effects and VPA serum level was established.
In eight epileptic patients receiving chronic antiepileptic treatment, a study of the excretion in sweat of phenytoin, phenobarbitone and carbamazepine was performed. All three drugs were found to be present in sweat. Phenytoin sweat concentration was found to correspond to the free fraction in plasma and to be independent of sweat flow. Phenobarbitone sweat concentration was found to increase with increasing sweat flow. Regarding drug level monitoring it is proposed that under changing climatic conditions the phenomenon may be of clinical significance.
Explore the source record for details and available documents.
Explore the source record for details and available documents.